BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

421 related articles for article (PubMed ID: 28614983)

  • 1. Second Primary Cancer in Patients with Differentiated Thyroid Cancer: Does Radioiodine Play a Role?
    Silva-Vieira M; Carrilho Vaz S; Esteves S; Ferreira TC; Limbert E; Salgado L; Leite V
    Thyroid; 2017 Aug; 27(8):1068-1076. PubMed ID: 28614983
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Radioactive Iodine Treatment for Children and Young Adults with Thyroid Cancer in South Korea: A Population-based Study.
    Seo GH; Kong KA; Kim BS; Kang SY; Moon BS; Yoon HJ; Kim HO
    J Clin Endocrinol Metab; 2021 Jun; 106(7):e2580-e2588. PubMed ID: 33755732
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Risk of second primary malignancy in differentiated thyroid carcinoma treated with radioactive iodine therapy.
    Lang BH; Wong IO; Wong KP; Cowling BJ; Wan KY
    Surgery; 2012 Jun; 151(6):844-50. PubMed ID: 22341041
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Increased Risk of Leukemia After Radioactive Iodine Therapy in Patients with Thyroid Cancer: A Nationwide, Population-Based Study in Korea.
    Seo GH; Cho YY; Chung JH; Kim SW
    Thyroid; 2015 Aug; 25(8):927-34. PubMed ID: 26133388
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rising incidence of second cancers in patients with low-risk (T1N0) thyroid cancer who receive radioactive iodine therapy.
    Iyer NG; Morris LG; Tuttle RM; Shaha AR; Ganly I
    Cancer; 2011 Oct; 117(19):4439-46. PubMed ID: 21432843
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Incidence of second primary malignancies during a long-term surveillance of patients with differentiated thyroid carcinoma in relation to radioiodine treatment.
    Fallahi B; Adabi K; Majidi M; Fard-Esfahani A; Heshmat R; Larijani B; Haghpanah V
    Clin Nucl Med; 2011 Apr; 36(4):277-82. PubMed ID: 21368600
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Incidence of Nonthyroidal Primary Malignancy and the Association with (131)I Treatment in Patients with Differentiated Thyroid Cancer.
    Hirsch D; Shohat T; Gorshtein A; Robenshtok E; Shimon I; Benbassat C
    Thyroid; 2016 Aug; 26(8):1110-6. PubMed ID: 27302111
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Use of Radioactive Iodine for Thyroid Cancer and Risk of Second Primary Malignancy: A Nationwide Population-Based Study.
    Teng CJ; Hu YW; Chen SC; Yeh CM; Chiang HL; Chen TJ; Liu CJ
    J Natl Cancer Inst; 2016 Feb; 108(2):. PubMed ID: 26538627
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Risk of Hematologic Malignancies After Radioiodine Treatment of Well-Differentiated Thyroid Cancer.
    Molenaar RJ; Sidana S; Radivoyevitch T; Advani AS; Gerds AT; Carraway HE; Angelini D; Kalaycio M; Nazha A; Adelstein DJ; Nasr C; Maciejewski JP; Majhail NS; Sekeres MA; Mukherjee S
    J Clin Oncol; 2018 Jun; 36(18):1831-1839. PubMed ID: 29252123
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Incidence of second primary cancers in North Portugal-a population-based study.
    Pacheco-Figueiredo L; Antunes L; Bento MJ; Lunet N
    J Cancer Surviv; 2016 Feb; 10(1):142-52. PubMed ID: 26159159
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nonthyroidal second primary malignancies in differentiated thyroid cancer patients: Is the incidence increased comparing to the general population and could it be a radioiodine therapy consequence?
    Cappagli V; Caldarella A; Manneschi G; Piaggi P; Bottici V; Agate L; Molinaro E; Bianchi F; Elisei R
    Int J Cancer; 2020 Nov; 147(10):2838-2846. PubMed ID: 32449158
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Second primary malignancies in thyroid cancer patients.
    Rubino C; de Vathaire F; Dottorini ME; Hall P; Schvartz C; Couette JE; Dondon MG; Abbas MT; Langlois C; Schlumberger M
    Br J Cancer; 2003 Nov; 89(9):1638-44. PubMed ID: 14583762
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Risk of second primary cancer following differentiated thyroid cancer.
    Berthe E; Henry-Amar M; Michels JJ; Rame JP; Berthet P; Babin E; Icard P; Samama G; Galateau-Sallé F; Mahoudeau J; Bardet S
    Eur J Nucl Med Mol Imaging; 2004 May; 31(5):685-91. PubMed ID: 14747959
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Increased risk of certain second primary malignancies in patients treated for well-differentiated thyroid cancer.
    Hakala TT; Sand JA; Jukkola A; Huhtala HS; Metso S; Kellokumpu-Lehtinen PL
    Int J Clin Oncol; 2016 Apr; 21(2):231-239. PubMed ID: 26410770
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Italian cancer figures, report 2013: Multiple tumours.
    AIRTUM Working Group
    Epidemiol Prev; 2013; 37(4-5 Suppl 1):1-152. PubMed ID: 24259384
    [TBL] [Abstract][Full Text] [Related]  

  • 16. (131)I treatment for thyroid cancer and the risk of developing salivary and lacrimal gland dysfunction and a second primary malignancy: a nationwide population-based cohort study.
    Ko KY; Kao CH; Lin CL; Huang WS; Yen RF
    Eur J Nucl Med Mol Imaging; 2015 Jul; 42(8):1172-8. PubMed ID: 25900274
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Second primary cancers occurring after I-125 brachytherapy as monotherapy for early prostate cancer.
    Musunuru H; Mason M; Murray L; Al-Qaisieh B; Bownes P; Smith J; Franks K; Carey B; Bottomley D; Henry AM
    Clin Oncol (R Coll Radiol); 2014 Apr; 26(4):210-5. PubMed ID: 24507938
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Risk of Breast Cancer in Patients with Thyroid Cancer Receiving or Not Receiving 131I Treatment: A Nationwide Population-Based Cohort Study.
    Lin CY; Lin CL; Huang WS; Kao CH
    J Nucl Med; 2016 May; 57(5):685-90. PubMed ID: 26719377
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pre-therapeutic blood dosimetry in patients with differentiated thyroid carcinoma using 124-iodine: predicted blood doses correlate with changes in blood cell counts after radioiodine therapy and depend on modes of TSH stimulation and number of preceding radioiodine therapies.
    Hartung-Knemeyer V; Nagarajah J; Jentzen W; Ruhlmann M; Freudenberg LS; Stahl AR; Bockisch A; Rosenbaum-Krumme SJ
    Ann Nucl Med; 2012 Nov; 26(9):723-9. PubMed ID: 22802008
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Outcomes of Thyrotropin Alfa Versus Levothyroxine Withdrawal-Aided Radioiodine Therapy for Distant Metastasis of Papillary Thyroid Cancer.
    Simões-Pereira J; Ferreira TC; Limbert E; Cavaco BM; Leite V
    Thyroid; 2021 Oct; 31(10):1514-1522. PubMed ID: 34155923
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 22.